Aclimostat
- Generic Name
- Aclimostat
- Drug Type
- Small Molecule
- Chemical Formula
- C26H42N2O6
- CAS Number
- 2082752-83-6
- Unique Ingredient Identifier
- X150A3JK8R
- Background
Aclimostat is under investigation in clinical trial NCT03254368 (Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes).
Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Type 2 Diabetes MellitusOverweight and Obesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2017-08-18
- Last Posted Date
- 2019-05-24
- Lead Sponsor
- Zafgen, Inc.
- Target Recruit Count
- 188
- Registration Number
- NCT03254368
- Locations
- 🇳🇿
Optimal Clinical Trials, Auckland, New Zealand
🇳🇿Wellington Hospital, Wellington, New Zealand
🇦🇺Coffs Harbour GP SuperClinic, Coffs Harbour, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath